Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
- Wedzicha, Jadwiga A
- Banerji, Donald
- Chapman, Kenneth R
- Vestbo, Jørgen
- Roche, Nicolas
- Ayers, R Timothy
- Thach, Chau
- Fogel, Robert
- Patalano, Francesco
- Vogelmeier, Claus F
Publication date
June 2016
DOI Publisher
Massachusetts Medical Society Journal
New England Journal of MedicineAbstract
Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear.status: publishe
Add to ORKG